Skip to main content

Table 5 Clinicopathological characteristics of the patients with D1 (n = 43) and D2 station metastasis (n = 22) set

From: The risk of lymph node metastasis in gastric cancer conforming to indications of endoscopic resection and pylorus-preserving gastrectomy: a single-center retrospective study

Factor

D1 stationa

D2 stationa

P-value

Age (years)

  < 40

37

18

0.655

  ≥ 40

6

4

 

Sex

 Male

26

12

0.647

 Female

17

10

 

Tumor size

 Length-diameter (cm)

2.938

2.917

0.295

 Short-diameter (cm)

2.303

2.000

0.243

   < 2 cm

9

2

0.163

   ≥ 2 cm

23

16

 

   < 3 cm

16

8

0.706

   ≥ 3 cm

16

10

 

Tumor marker

 CEA (U/mL)

3.189

6.861

0.003

 CA125 (U/mL)

9.702

10.568

0.165

 CA199 (U/mL)

10.113

30.125

0.001

Tumor location

  

0.171

 Upper

3

3

 

 Middle

22

6

 

 Lower

18

13

 

Depth of invasion

  

0.322

 Intra-mucosal

16

11

 

 Submucosa

27

11

 

Differentiated

 Well-Moderately

8

6

0.421

 Poorly

35

16

 

LVI

 Absent

48

10

0.940

 Present

9

2

 
  1. For total gastrectomy: D1: Nos. 1–7; D1+: D1 + Nos. 8a, 9, 11p; D2: D1 + Nos. 8a, 9, 11p, 11d, 12a
  2. For distal gastrectomy: D1: Nos. 1, 3, 4sb, 4d, 5, 6, 7; D1+: D1 + Nos. 8a, 9; D2: D1 + 8a, 9, 11p, 12a
  3. For pylorus-preserving gastrectomy: D1: Nos. 1, 3, 4sb, 4d, 6, 7; D1+: Nos. 8a, 9
  4. For proximal gastrectomy: D1: Nos. 1, 2, 3 s, 4sa, 4sb, 7; D1+: D1 + Nos. 8a, 9, 11p
  5. LVI lymphovascular invasion, CEA carcinoembryonic antigen, CA125 cancer antigen 125, CA199 cancer antigen 199
  6. aAccording to the Japanese gastric cancer treatment guidelines 2018 (5th edition)